R&S GROUP HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.6 CHF | +6.91% |
|
+7.41% | +9.43% |
| May. 17 | R&S Group Raises FY24 Revenue Outlook | MT |
| May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Electrical Components & Equipment
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +9.43% | 357M | - | ||
| +7.48% | 46.24B | B+ | ||
| +162.47% | 5.05B | B | ||
| -1.53% | 2.84B | C- | ||
| -2.92% | 2.8B | D | ||
| +102.30% | 1.29B | - | ||
| -31.20% | 1.1B | D+ | ||
| -8.88% | 1B | B- | ||
| +50.47% | 971M | - | ||
| -15.43% | 909M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RSGN Stock
- Ratings R&S Group Holding AG
